Published in J Pharmacol Exp Ther on September 01, 2002
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med (2005) 0.99
Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinology (2012) 0.98
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob Agents Chemother (2007) 0.98
Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem (2010) 0.97
Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother (2010) 0.92
Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther (2009) 0.87
Interleukin-1β transfer across the blood-brain barrier in the ovine fetus. J Cereb Blood Flow Metab (2015) 0.87
Global hormone profiling of murine placenta reveals Secretin expression. Placenta (2011) 0.83
Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med (2010) 0.82
Secretin as a treatment for autism: a review of the evidence. J Autism Dev Disord (2004) 0.81
Inhibition of fear potentiated startle in rats following peripheral administration of secretin. Psychopharmacology (Berl) (2003) 0.78
The role of dietary antioxidant insufficiency on the permeability of the blood-brain barrier. J Neuropathol Exp Neurol (2008) 0.76
Vagal afferent mediates the anorectic effect of peripheral secretin. PLoS One (2013) 0.76
Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. Clin Pract Epidemiol Ment Health (2005) 0.75
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides. Front Endocrinol (Lausanne) (2017) 0.75
The central mechanisms of secretin in regulating multiple behaviors. Front Endocrinol (Lausanne) (2014) 0.75
A role for skin gammadelta T cells in wound repair. Science (2002) 3.51
HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci (2011) 3.06
Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A (2002) 2.69
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A (2013) 1.82
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol (2009) 1.70
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One (2010) 1.58
Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides (2007) 1.35
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis (2011) 1.29
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther (2004) 1.23
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis (2012) 1.23
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Epigenetic therapy for Friedreich ataxia. Ann Neurol (2014) 1.11
Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res (2002) 1.09
Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther (2003) 1.08
Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol (2004) 1.07
Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab (2008) 1.01
Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J Neurochem (2013) 1.01
The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet (2013) 0.99
Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression. Epigenetics Chromatin (2013) 0.97
Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol (2010) 0.96
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol (2012) 0.95
A gene expression phenotype in lymphocytes from Friedreich ataxia patients. Ann Neurol (2011) 0.94
Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis (2012) 0.94
Passage of murine scrapie prion protein across the mouse vascular blood-brain barrier. Biochem Biophys Res Commun (2004) 0.92
Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis (2012) 0.92
Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS One (2013) 0.89
A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. J Pharmacol Exp Ther (2010) 0.86
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol (2011) 0.85
Permeability of the mouse blood-brain barrier to murine interleukin-2: predominance of a saturable efflux system. Brain Behav Immun (2004) 0.85
Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. Eur J Pharmacol (2003) 0.84
Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol (2008) 0.83
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.82
Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target (2009) 0.82
Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice. Eur J Pharmacol (2010) 0.81
Transport of an antifungal trypsin inhibitor isolated from corn across the blood-brain barrier. Antimicrob Agents Chemother (2002) 0.80
Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study. Free Radic Biol Med (2013) 0.80
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism Relat Disord (2012) 0.80
Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res (2006) 0.79
Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther (2006) 0.79
Age-related and regional differences in secretin and secretin receptor mRNA levels in the rat brain. Neurosci Lett (2004) 0.79
Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake. FASEB J (2011) 0.79
Secretin depolarizes nucleus tractus solitarius neurons through activation of a nonselective cationic conductance. Am J Physiol Regul Integr Comp Physiol (2004) 0.79
Effects of uridine in models of epileptogenesis and seizures. Epilepsy Res (2006) 0.78
Inhibition of fear potentiated startle in rats following peripheral administration of secretin. Psychopharmacology (Berl) (2003) 0.78
Dietary nucleotides prevent decrease in cellular immunity in ground-based microgravity analog. J Appl Physiol (1985) (2002) 0.77
Effects of chronic ethanol on brain and serum level of methionine enkephalin. Peptides (2003) 0.77
Pharmacokinetics and modeling of immune cell trafficking: quantifying differential influences of target tissues versus lymphocytes in SJL and lipopolysaccharide-treated mice. J Neuroinflammation (2012) 0.77
Partial reversal of phencyclidine-induced impairment of prepulse inhibition by secretin. Biol Psychiatry (2005) 0.76
Increased amygdala fMRI activation after secretin administration. Exp Clin Psychopharmacol (2008) 0.75
Lack of effect of secretin on kindling and seizures. Epilepsy Behav (2006) 0.75
Effects of uridine on kindling. Epilepsy Behav (2008) 0.75